(P167) INSIGHTS INTO HEART FAILURE MANAGEMENT: PRELIMINARY FINDINGS FROM THE VISION C+ REGISTRY

Background: Heart failure (HF) affects over 750,000 Canadians, with 100 000 being diagnosed each year. Despite healthcare advancements, challenges persist in standardizing data collection and analysis across systems, thereby impeding comprehensive understanding and optimization of HF care. Utilizing robust clinical data repositories like the Vision C+ registry, established in 1998 by the Quebec Heart Failure Society, is essential to address these challenges. Through detailed analysis of patient demographics, clinical variables, and treatment modalities, this study aims to identify patterns and areas for enhancement in HF management. This research addresses the critical importance of using registry data to drive evidence-based insights aimed at improving patient outcomes in HF care. We herein provide preliminary findings of HF management in Quebec, using the Vision C+ registry.

METHODS AND RESULTS: The Vision C+ Registry is a structured electronic medical record (EMR) of patients treated for HF in 41 specialized clinics across Quebec since 1998. It includes 34 categories of variables such as demographics, cardiac and medical history, clinical evaluation and laboratory data, medications, natural health products (NHP), etc. Patients are linked with a unique crypted identification number. Descriptive analysis was performed.

As of December 2021, the Registry contained data of 64,150 patients (24% alive, 29% dead, 47% inactive) The mean age was 74±16 years, 35% were female, with ischemic etiology being the cause of HF in the majority (50%), and almost two third having heart failure with reduced ejection fraction (HFrEF, Table 1). Patients were symptomatic of NYHA class II (14370 patients, 49%), III (11933, 41%) or IV (656, 2%), while only 2258 patients (8%) were NYHA class I. Prevalent comorbidities included, hypertension (65%), dyslipidemia (55%), diabetes (38%) and chronic kidney disease (32%). Additionally, 471 patients used NHP and over the counter medicines. Guideline-directed medical therapy for HF patient is currently being analyzed.

Conclusion: The Vision C+ EMR is a valuable asset for advancing HF research. The preliminary findings provide valuable insights into the demographics of HF in Quebec, which are important for optimizing care for HF patients.